Last reviewed · How we verify
Etoposide with Carboplatin or Cisplatin — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Etoposide with Carboplatin or Cisplatin (Etoposide with Carboplatin or Cisplatin) — Trans Tasman Radiation Oncology Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Etoposide with Carboplatin or Cisplatin TARGET | Etoposide with Carboplatin or Cisplatin | Trans Tasman Radiation Oncology Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Etoposide with Carboplatin or Cisplatin CI watch — RSS
- Etoposide with Carboplatin or Cisplatin CI watch — Atom
- Etoposide with Carboplatin or Cisplatin CI watch — JSON
- Etoposide with Carboplatin or Cisplatin alone — RSS
Cite this brief
Drug Landscape (2026). Etoposide with Carboplatin or Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/etoposide-with-carboplatin-or-cisplatin. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab